| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On May 31, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| 2000P-1378
|
| Cosmetic Products Containing Alpha Hydroxy Acids
|
|
|
|
|
| 2002P-0399
|
| Determine Whether Estrostep 21 Tablets, NDA 020130 Have Been
|
|
|
|
|
| 2005N-0272
|
| Irradiation in the Production, Processing, and Handling of Food
|
|
|
|
|
| 2005N-0279
|
| Food Labeling; Gluten-Free Labeling of Foods
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| 2006D-0336
|
| Guidance for Industry and Food and Drug Administration Staff; Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions
|
|
|
|
|
| 2006D-0347
|
| Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays
|
|
|
|
|
| 2006N-0479
|
| Insect Repellent-Sunscreen Drug Products for Over-the-Counter Human Use
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2006P-0484
|
| Change the indication for Stimulant Medications for the Treatment of Mental Diseases
|
|
|
|
|
| 2006P-0491
|
| make a determination that the withdrawal of the Reference Listed Drug (RLD), Psorcon E (diflorasone diacetate oin tment) Emollient , Ointment, 0.05%, was not for safety or effectiveness reasons.
|
|
|
|
|
| 2006P-0498
|
| Use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods
|
|
|
|
|
| 2007N-0068
|
| Medical Device User Fee and Modernization Act: Public Meeting
|
|
|
|
|
| 2007N-0090
|
| Zimulti Endocrinologic and Metabolic Drugs Advisory Committee Meeting, June 13, 2007
|
|
|
|
|
| 2007N-0121
|
| Use of Medication Guides to Distribute Drug Risk Information to Patients; Public Hearing
|
|
|
|
|
| 2007V-0088
|
| Projector for a Laser Light Show
|
|
| |
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| ACK 21
|
| FDA/DDM to Office of the Connecticut Attorney General
|
| Vol #:
|
| 150
|
|
|
|
|
| CP 19
|
| Office of the Connecticut Attorney General
|
| Vol #:
|
| 150
|
|
|
|
|
| 2000P-1378
|
| Cosmetic Products Containing Alpha Hydroxy Acids
|
|
|
|
|
| NCR 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2002P-0399
|
| Determine Whether Estrostep 21 Tablets, NDA 020130 Have Been
|
|
|
|
|
| LET 2
|
| FDA/CDER to Barr Laboratories, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0272
|
| Irradiation in the Production, Processing, and Handling of Food
|
|
|
|
|
| EC 225
|
| Ms. Barbara Brown
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 226
|
| Mr. Dennis Lawrence
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 227
|
| Mrs. Laurie Ann Lawrence
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 228
|
| Mr. D. Michael Lawrence, Jr
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 229
|
| Dr. Ruth Molin
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 230
|
| Ms. Gloria Brady
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 231
|
| Mrs. Christy Peterson
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 232
|
| Mrs. Kevin Riley
|
| Vol #:
|
| 6
|
|
| | | | | | | | |
|
| |
|
| EC 270
|
| Mrs. Donna Correll
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 271
|
| Mrs. Darlene Church
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 272
|
| Mrs. betty shamas
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 273
|
| Mr. Leslie Johnson
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 274
|
| Mrs. Dorothy Capes
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 275
|
| Mr. Dean Mindock
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 276
|
| Ms. Robin Appel
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 277
|
| Mrs. Brenda Trinka
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 278
|
| Weston A. Price Foundation
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 279
|
| Mr. Daniel Ziese
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 280
|
| Ms. G Liu
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 281
|
| Mrs. Melinda Orms
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 282
|
| Ms. Barbara Frost
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 283
|
| Mrs. Susan Worth
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 284
|
| Ms. Sheryl Buntin
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 285
|
| Mr. bob billings
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 286
|
| Mrs. Judy Leroux
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 287
|
| Mr. Timothy Geib
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 288
|
| Mr. Dan LeBar
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 289
|
| Mr. Sam Leandro
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 290
|
| Mrs. frieda reiz
|
| Vol #:
|
| 6
|
|
|
|
|
| EC 291
|
| Dr. Tona Ball
|
| Vol #:
|
| 6
|
|
|
|
|
| 2005N-0279
|
| Food Labeling; Gluten-Free Labeling of Foods
|
|
|
|
|
| C 741
|
| Ministry for Foreign Affairs of Finland
|
| Vol #:
|
| 35
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| C 18309
|
| L. Whiting
|
| Vol #:
|
| 198
|
|
|
|
|
| C 18310
|
| C. Thompson
|
| Vol #:
|
| 198
|
|
|
|
|
| 2006D-0336
|
| Guidance for Industry and Food and Drug Administration Staff; Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions
|
|
|
|
|
| MM 1
|
| FDA & 21st Century Medicine Coalition
|
| Vol #:
|
| 1
|
|
| |
|
| 2006D-0347
|
| Guidance for Industry, Clinical Laboratories, and FDA Staff on In Vitro Diagnostic Multivariate Index Assays
|
|
|
|
|
| MM 1
|
| FDA and 21st Century Medicine Coalition
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0479
|
| Insect Repellent-Sunscreen Drug Products for Over-the-Counter Human Use
|
|
|
|
|
| C 3
|
| Chattem, Inc.
|
| Vol #:
|
| 1
|
|
| | | | | | | | |
|
| |
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| C 95
|
| K Crupi
|
| Vol #:
|
| 7
|
|
|
|
|
| C 96
|
| A Hilbink
|
| Vol #:
|
| 7
|
|
|
|
|
| C 97
|
| N Shah
|
| Vol #:
|
| 7
|
|
|
|
|
| EC 1145
|
| Ms. Janis Lindenberger
|
| Vol #:
|
| 9
|
|
|
|
|
| EC 1146
|
| Mr. James Lindenberger
|
| Vol #:
|
| 9
|
|
|
|
|
| 2006P-0484
|
| Change the indication for Stimulant Medications for the Treatment of Mental Diseases
|
|
|
|
|
| PDN 1
|
| FDA/CDER to M Poff McDole
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0491
|
| make a determination that the withdrawal of the Reference Listed Drug (RLD), Psorcon E (diflorasone diacetate oin tment) Emollient , Ointment, 0.05%, was not for safety or effectiveness reasons.
|
|
|
|
|
|
| |
|
|
|
| LET 1
|
| FDA/CDER to Kirkpatrick & Lockhart Preston Gates Ellis, LLP
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0498
|
| Use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods
|
|
|
|
|
| C 94
|
| Forrest General Hospital
|
| Vol #:
|
| 4
|
|
|
|
|
| 2007N-0068
|
| Medical Device User Fee and Modernization Act: Public Meeting
|
|
|
|
|
| C 3
|
| Vivosonic, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0090
|
| Zimulti Endocrinologic and Metabolic Drugs Advisory Committee Meeting, June 13, 2007
|
|
|
|
|
| C 1
|
| D Windsor MD
|
| Vol #:
|
| 1
|
|
|
|
|
| C 2
|
| The Obesity Society
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 3
|
| Mr. D Bulmer
|
| Vol #:
|
| 1
|
|
| |
|
| 2007N-0121
|
| Use of Medication Guides to Distribute Drug Risk Information to Patients; Public Hearing
|
|
|
|
|
| EAPE 235
|
| Grijalva, Juan Carlos
|
| Vol #:
|
| 7
|
|
|
|
|
| EAPE 236
|
| Sisk, Janet
|
| Vol #:
|
| 7
|
|
|
|
|
| 2007V-0088
|
| Projector for a Laser Light Show
|
|
|
|
|
| VRA 1
|
| FDA/CDRH to Platinum Graphics
|
| Vol #:
|
| 1
|
|
